| Literature DB >> 11886380 |
Ugo Consoli1, AnnaMaria Santonocito, Fabio Stagno, Paolo Fiumara, Antonella Privitera, Giuseppina Parisi, Giada M Giustolisi, Biagia Pavone, Giuseppe A Palumbo, Francesco Di Raimondo, Giuseppe Milone, Patrizia Guglielmo, Rosario Giustolisi.
Abstract
We evaluated the presence of P-glycoprotein (P-gp)-170, multidrug resistance protein (MRP), lung resistance protein (LRP)-56 and Bcl-2 in CD19-positive cells from 100 cases of chronic lymphocytic leukaemia (CLL). P-gp-170 was found in 73% of the CLL cases with no significant difference regarding stage or previous treatment. LRP-56 protein was homogeneously distributed with no differences for stage or treatment. MRP protein was detected at a low level of expression in 49.4% of CLL patients with no differences for stage or treatment. Bcl-2 protein was expressed at a high level in all CLL patients and higher levels were found in the advanced stage. This leads us to conclude that P-gp, MRP, LRP-56 and Bcl-2 are frequently expressed in CLL. P-gp, MRP and LRP are not correlated to stage or previous treatment. Bcl-2 is higher in advanced-stage patients. The clinical and biological significance of these zMDR mechanisms in CLL remains to be fully explained.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11886380 DOI： 10.1046/j.0007-1048.2002.03344.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998